Positive topline results from client Phase 2b field study

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that on Friday 30 May 2025, Yamin ‘Mo’ Khan, Chief

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that it has received notification of a significant human challenge

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that further to its announcement on 12 May 2025, the

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that the Company’s Annual Report and Accounts for the year

hVIVO Plc (HVO) is a specialist contract research organisation (CRO) and a world leader in conducting human challenge trials for infectious and respiratory disease vaccines and therapeutics.

Final results Record revenue and EBITDA Key strategic progress post year end in diversification of business

hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (“CRO”) and the world leader in human challenge clinical trials, announces that it will release its final results for the

Acquisition of Cryostore for up to £3.2 million Immediately earnings enhancing acquisition of bio-storage supplier

hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that, following the success of its pilot human metapneumovirus

Shionogi reports positive results from RSV antiviral human challenge trial conducted by hVIVO Human challenge trials provide valuable insights to accelerate candidate development